| 4.64 0.04 (0.87%) | 09-13 00:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.53 | 1-year : | 6.46 |
| Resists | First : | 4.73 | Second : | 5.53 |
| Pivot price | 4.59 |
|||
| Supports | First : | 3.74 | Second : | 3.13 |
| MAs | MA(5) : | 4.63 | MA(20) : | 4.39 |
| MA(100) : | 3.97 |
MA(250) : | 6.23  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 90.1 |
| RSI | RSI(14): 70.7 | |||
| 52-week | High : | 78.81 | Low : | 2.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADGI ] has closed below upper band by 43.3%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.74 - 4.77 | 4.77 - 4.79 |
| Low: | 4.35 - 4.37 | 4.37 - 4.39 |
| Close: | 4.6 - 4.64 | 4.64 - 4.68 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Mon, 12 Sep 2022
Adagio Therapeutics Announces Corporate Name Change to Invivyd - Yahoo Finance
Wed, 23 Mar 2022
2 Net Current Asset Value Stocks to Consider - Yahoo Finance
Thu, 23 Dec 2021
Galera Therapeutics Inc. (NASDAQ: GRTX) Announced Updated Findings Of Phase 3 ROMAN Study of Evasopasem in TY-induced SOM - BP Journal
Wed, 15 Dec 2021
Top 5 IPOs of 2021 - Investopedia
Tue, 14 Dec 2021
Adagio Therapeutics’ stock slides after presenting negative Omicron data - Drug Discovery & Development
Mon, 29 Nov 2021
5 Bold Predictions for 2022 and Beyond - Banyan Hill Publishing
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 32.5 (%) |
| Held by Institutions | 67.1 (%) |
| Shares Short | 3,920 (K) |
| Shares Short P.Month | 4,380 (K) |
| EPS | -14.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -220 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|